News
Public · Published
Evommune licenses Hinova autoimmune drug in up to $1.1 billion deal
Evommune licensed rights outside Greater China to develop, manufacture and sell Hinova's experimental oral autoimmune drug EVO570. It will pay $30 million upfront, including cash and pre-funded warrants, while Hinova could receive up to $1.1 billion in milestone payments plus royalties. Evommune plans a mid-stage rheumatoid arthritis study in 2027.
Published:
Updated:
What happened
Evommune licensed rights outside Greater China to develop, manufacture and sell Hinova’s experimental oral autoimmune drug EVO570. It will pay $30 million upfront, including cash and pre-funded warrants, while Hinova could receive up to $1.1 billion in milestone payments plus royalties. Evommune plans a mid-stage rheumatoid arthritis study in 2027.
Confirmed
Global impact / market context
The agreement gives Evommune a potential new drug program and access to research targeting VAV1, a protein involved in activating immune cells. If development succeeds, later milestone payments and royalties would cost Evommune money, while commercial sales could add revenue; the upfront payment is an immediate funding commitment.
Analyst inference
The headline’s up to $1.1 billion is conditional milestone payments, not an upfront purchase price or guaranteed payment. The confirmed initial payment is $30 million, split between cash and warrants, which can be used to buy Evommune stock; future royalties depend on sales.
Confirmed
What to watch
- Watch for details of the planned 2027 mid-stage rheumatoid arthritis study, including whether it starts on schedule and what results indicate about EVO570’s safety and effectiveness. Confirmed
- Track whether development, regulatory and commercial milestones are achieved; these conditions determine how much of the potential $1.1 billion Hinova receives and when Evommune pays. Analyst inference
- Monitor whether the pre-funded warrants are used to purchase Evommune stock and how any future sales and tiered royalties affect the companies’ cash and revenue. Analyst inference
Evidence
- Original source link unavailable